北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 泌尿外科  > 期刊论文
学科主题: 泌尿外科学
题名:
舒尼替尼治疗转移性肾细胞癌的疗效和不良反应及其相关性分析
其他题名: Efficacy and safety of sunitinib in treating metastatic renal cell carcinoma
作者: 蔡林; 张崔建; 李学松; 宋毅; 虞巍; 张骞; 何志嵩; 周利群
关键词: 舒尼替尼 ; 肾肿瘤 ; 转移 ; 有效性 ; 不良反应 ; Sunitinib ; Kidney neoplasms ; Metastatic ; Efficacy ; Adverse events
刊名: 中华泌尿外科杂志
发表日期: 2014
DOI: 10.3760/cma.j.issn.1000-6702.2014.06.007
卷: 35, 期:6, 页:425-428
收录类别: 中国科技核心期刊 ; 中文核心期刊 ; CSCD
文章类型: Journal Article
摘要: 目的 评价舒尼替尼治疗转移性肾细胞癌的疗效及安全性,并分析疗效与不良反应的相关性. 方法 2008年6月至2013年3月91例转移性肾细胞癌患者接受舒尼替尼治疗.其中男73例,女18例.年龄17~77岁,中位年龄58岁.行根治性肾切除术83例,肾穿刺活检或转移灶穿刺活检8例.肾透明细胞癌86例,肾乳头状细胞癌4例,未分类肾癌1例.一线治疗77例,细胞因子治疗失败者8例,索拉非尼治疗进展后二线治疗6例.81例口服舒尼替尼50 mg/d 4周,停药2周,6周为1个周期;10例口服舒尼替尼37.5 mg/d,持续用药.治疗期间根据不良反应的严重程度调整用药,直至出现疾病进展或出现不可耐受的不良反应. 结果 中位随访时间19.0个月.完全缓解2例(2.2%),部分缓解23例(25.3%),疾病稳定57例(62.6%),疾病进展9例(9.9%).客观缓解率为27.5%,疾病控制率为90.1%.获得疾病控制患者达到最佳疗效的中位时间为5.5个月(2.0~27.0个月).中位无疾病进展时间15.5个月.主要不良反应包括血小板减少71例(78.0%),甲状腺功能异常43例(76.8%,43/56),手足皮肤反应68例(74.7%),白细胞减少57例(62.6%),高血压44例(48.4%),乏力43例(47.3%).3~4级不良反应38例,主要包括血小板减少14例、中性粒细胞减少8例、手足皮肤反应7例及甲状腺功能异常6例.31例(34.1%)患者因不良反应需要调整药物剂量或短暂停药,多数患者经对症支持后可继续治疗,2例患者分别因严重乏力和心肌梗死中断治疗.出现1~2级不良反应与出现3~4级不良反应患者的中位无疾病进展生存期分别为11.5个月和18.0个月(p=0.04). 结论 舒尼替尼用于治疗转移性肾细胞癌患者具有较好的疗效和安全性,可获得较长的无进展生存期.多数不良反应可以耐受,出现3~4级不良反应可能是治疗有效的预测因子. Objective To evaluate the efficacy,safety and their correlation of sunitinib in the treatment of metastatic renal cell carcinoma (mRCC).Methods Ninety-one cases with mRCC were treated with sunitinib between June 2008 and March 2013,including 73 males and 18 females.The median age was 58 (17-77) years.All patients were diagnosed as RCC,which consisted of 86 clear cell carcinomas,4 papillary cell carcinomas and 1 unclassified RCC.Seventy-seven cases were treated with first line therapy and 14 cases showed progression on first-line cytokine or sorafinib therapy.Daily oral sunitinib monotherapy was administered for 4 weeks,followed by 2 weeks off by repeated 6-week cycles in 81 patients,while another 10 patients received 37.5 mg Qd continuously until disease progression or unacceptable toxicities occurred.Results The median follow-up was 19.0 months.Two (2.2%) patients achieved complete responses,23 (25.3%) patients achieved partial responses,57 (62.6%) patients demonstrated stable disease for ≥ 3 months and 9 (9.9%) patients developed progressive disease.The objective response rate was 27.5%,and the disease control rate was 90.1%.The median progression-free survival (PFS) was 15.5 months.The most common treatment-related adverse events were thrombocytopenia (71 cases,78.0%),thyroid dysfunction (43/56,76.8%),hand-foot syndrome(68 cases,74.7%),leucopenia (57 cases,62.6%),hypertension (44 cases,48.4%),fatigue (43 cases,47.3%).The grade 3-4 major adverse events (38 cases) included thrombocytopenia (14 cases),neutropenia(8 cases),hand-foot syndrome (7 cases) and thyroid dysfunction (6 cases).Thirty-one (34.1%) patients had dose decrement or drug discontinuation.Two patients withdrew fiom treatment for intolerable fatigue and cardiac infarction.The median PFS was significantly improved in patients with grade 3-4 adverse events compared with those with only grade 1-2 adverse events(18.0 versus 11.5 months,P=0.04).Conclusions The efficacy of sunitinib in patients with mRCC is encouraging.At the same time,the tolerability is good.Sunitinib-associated severe adverse events may be a predictive marker for treatment efficacy in mRCC.
语种: 中文
原文出处: 查看原文
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/44996
Appears in Collections:北京大学第一临床医学院_泌尿外科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 100034,北京大学第一医院泌尿外科北京大学泌尿外科研究所

Recommended Citation:
蔡林,张崔建,李学松,等. 舒尼替尼治疗转移性肾细胞癌的疗效和不良反应及其相关性分析[J]. 中华泌尿外科杂志,2014,35(6):425-428.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[蔡林]'s Articles
[张崔建]'s Articles
[李学松]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[蔡林]‘s Articles
[张崔建]‘s Articles
[李学松]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace